Announcements Trials
Browse Landscape

Phase

Phase 1 42Phase 2 34Phase 1/2 14Phase 3 13Phase NA 12Phase EARLY_PHASE1 3Phase 2/3 2Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Glioblastoma 1

Interventions

Saline Solution 6Dexmedetomidine 5Sodium Chloride 4Temozolomide 3Sevoflurane 3Propofol 3Methotrexate 3Levetiracetam 3trametinib 2perampanel 2dabrafenib 2Sugammadex 2Neuroimaging 2Methylphenidate 2Magnetic Resonance Spectroscopy 2Granulocyte-Macrophage Colony-Stimulating Factor 2Gentamicins 2Fluorescein 2Anesthesia, Inhalation 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1pembrolizumab 1pegvisomant 1olutasidenib 1naxitamab 1lorlatinib 1gadoterate meglumine 1gadobenic acid 1durvalumab 1dexketoprofen trometamol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Radiation × CNS × Clear all
NCT00686725 2017-06-14

Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)

Merck Sharp & Dohme LLC

Phase 4 Completed
99 enrolled 15 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡